Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016;1(1):1-14.
Epub 2016 Apr 28.

Regulatory T-Cell Therapy for Graft-versus-host Disease

Affiliations

Regulatory T-Cell Therapy for Graft-versus-host Disease

Jessica Heinrichs et al. J Immunol Res Ther. 2016.

Abstract

Graft-versus-host disease (GVHD) is a significant cause of non-relapse mortality after allogeneic hematopoietic cell transplantation (allo-HCT). Existing strategies to prevent and treat GVHD are incomplete, where a significant portion of allo-HCT recipients developed this complication. Despite this, one such therapy has emerged involving the use of regulatory T cells (Tregs) to control GVHD. The use of natural Tregs (nTregs) yielded positive pre-clinical results and are actively under investigation to reduce GVHD. However, broad application of this approach may require standardization of Treg expansion methods and dosing. Inducible Tregs (iTregs) can be seamlessly generated, but controversial pre-clinical findings and phenotype instability have hampered their translation into the clinic. Here, we review the current biological differences between nTregs and iTregs, as well as their effects on GVHD and graft-versus-leukemia (GVL) responses. We conclude by exploring the idea of combinational cellular therapies for the prevention of GVHD and preservation of GVL.

Keywords: Cellular therapy; Graft-versus-host disease (GVHD); iTregs; nTregs.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Delicate Balance between GVH and GVL responses
Following allogeneic HSCT, effector T cells within the graft inoculum recognize non-hematopoietic and hematopoietic allo-antigens presented by host and/or donor APCs resulting in both graft-versus-host (GVH) and graft-versus-leukemia (GVL) responses. Treg therapy could improve outcomes in allo-HSCT by greatly inhibiting Teffs cells causing GVHD with little or partial inhibition of the GVL effect.
Figure 2
Figure 2. Comparison of nTregs and iTregs: Generation, Suppressive Mechanism, and Stability
For generation nTregs and iTregs are distinct, with nTregs requiring recognition of self-antigen, costimulation, and IL-2; whereas iTregs recognize foreign antigen and require IL-2, TGFβ, and RA. nTregs and iTregs share suppressive mechanisms, broadly defined as direct cytolysis, suppressive cytokines, metabolic disruption, IL-2 deprivation, and contact dependent suppression. nTregs are more stable than iTregs with a fully demethylated CNS2 region with the foxp3 gene whereas iTregs sometimes display a partially methylated CNS2.

References

    1. Pidala J, Lee SJ, Ahn KW, Spellman S, Wang HL, et al. Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. Blood. 2014;124:2596–606. - PMC - PubMed
    1. Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg JH, et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med. 1996;334:281–285. - PubMed
    1. Fu J, Heinrichs J, Yu XZ. Helper T-cell differentiation in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Arch Immunol Ther Exp (Warsz) 2014;62:277–301. - PubMed
    1. Pasquini MC, Z X. Current uses and outcomes of hematopoietic stem cell transplantation: 2014 CIBMTR Summary Slides 2014
    1. Brunstein CG, Blazar BR, Miller JS, Cao Q, Hippen KL, et al. Adoptive transfer of umbilical cord blood-derived regulatory T cells and early viral reactivation. Biol Blood Marrow Transplant. 2013;19:1271–1273. - PMC - PubMed

LinkOut - more resources